Nutritional contributions to the CNS pathophysiology of HIV-1 infection and implications for treatment

CNS Spectrums

Volumn 5, Issue 4, 2000, Pages 61-72

  Baldewicz, Teri T ^a,c   Brouwers, Pirn ^a,b   Goodkin, Karl ^a,b   Kumar, Adarsh M ^a,b   Kumar, Mahendra ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Department of Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; CYANOCOBALAMIN; FOLIC ACID; METHIONINE; OMEGA 3 FATTY ACID; PYRIDOXINE; RETINOL; SELENIUM; TRYPTOPHAN; ZINC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DEMYELINATING DISEASE; DIET SUPPLEMENTATION; DRUG INDUCED DISEASE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; NONHUMAN; NUTRITIONAL DEFICIENCY; NUTRITIONAL SUPPORT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SPINAL CORD DISEASE; SUBSTANCE ABUSE; VIRUS INFECTION;

EID: 0034094047     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900013122     Document Type: Review

References (141)

1. Baum MK, Shor-Posner G. Micronutrient status in relationship to mortality in HIV-1 disease. Nutr Rev. 1998;56:S135-S139.
2. Chlebowski RT, Grosvenor MB, Bernhard NH, Morales LS, Bulcavage LM. Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol. 1989;84:1288-1293. û
3. Macallan DC, Noble C, Baldwin C, Foskett M, McManus T, Griffin GE. Prospective analysis of patterns of weight change in stage IV human immunodeficiency virus infection. Am J Clin Nutr. 1993;58:417-424.
4. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal miyRep. 1992;41(No.RR-17):l-19.
5. Shevitz AH, Know TA, Spiegelman D, Roubenoff R, Gorbach SL, Skolnik PR. Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. AIDS. 1999;13:1351-1357.
6. Baum M K, Shor-Posner G, Bonvehi P, et al. Influence of HIV infection on vitamin status and requirements. Ann N Y Acad Sci. 1992;699:165-174.
7. Baum M, Cassetti L, Bonvehi P, Shor-Posner G, Lu Y, Sauberlich H. Inadequate dietaryintake and altered nutrition status in early HIV-1 infection. Nutrition. 1994;10:16-20.
8. Niyongabo T, Bouchaud 0, Henzel D, et al. Nutritional status of HIV-seropositive subjects in an AIDS clinic in Paris. Eur J Clin Nutr. 1997;51:637-640.
9. Suttmann U, Ockenga J, Selberg 0, Hoogestraat L, Deicher H, Muller MJ. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. J Acquir Immune Defic S)-ndr Hum Retrorirol. 1995;8:239-246.
10. Abrams B, Duncan D, Hertz-Picciotto I. A prospective study of dietary intake and acquired immune deficiency syndrome in HIV-seropositive homosexual men. / Acquir Immune Defic Syndr Hum Retroiirol. 1993;6:949-958.
11. Skurnick JH, Bogden JD, Baker H, et al. Micronutrient profiles in HIV-1 infected heterosexual adults. J Acquir Immune Defic S)ndr Hum Retroi-irol. 1996;12:75-83.
12. Beach RS, Mantero-Atienza E, Shor-Posner G, et al. Specific nutrient abnormalities in asymptomatic HIV-1 infection. AIDS. 1992;6:701-708.
13. Eglen RM, Wong EHF, Dumuis A, Bockaert J. Central 5-HT4 receptors. Trends Pharmacol Sci. 1995;16:391-398.
14. Hodges RE, Bean WB, Ohlson MA, Bleiler RE. Factors affecting human antibody response. IV. Pyridoxine deficiency. Am J Clin Nutr. 1962;11:180-186.
15. Wilkie F, Shor-Posner G, Mantero-Atienza E, et al. Association of vitamin B,; status and reaction time in early HIV-1 infection. Neurological and Neuropsychological Complications of HIV Infection. 1991;2:67.
16. Baldewicz T, Goodkin K, Feaster DJ, et al. Plasma pyridoxine deficiency is related to increased psychological distress in recently bereaved homosexual men. Psychosom Med. 1998;60:297-308.
17. Shor-Posner G, Feaster D, Blaney NT, et al. Impact of vitamin B6 status on psychological distress in a longitudinal study of HIV-1 infection. Int ] Psychiatry Med. 1994;24:209-222.
18. Wurtman RJ. Food for thought. The Sciences. 1978;18:6-9.
19. Park SB, Coull JT, McShane RH, et al. Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. Neuropharmacology. 1994;33:575-588.
20. Faustman WO, Faull KF, Whiteford HA, Borchert C, Csernansky JG. CSF 5-HIAA, serum Cortisol, and age differentially predict vegetative and cognitive symptoms in depression. Biol Psychiatry. 1990;27:311-318.
21. Singer EJ, Wilkins J, Syndulko K, et al. Cerebrospinal fluid (CSF) biogenic amines increase and cortisol levels decrease after zidovudine (AZT) therapy in subjects with AIDS dementia complex (ADC). Neurological and Neuropsychological Complications of HIV Infection. Program and abstracts. 1990;145.
22. Brouwers P, Heyes MP, Moss HA, et al. Quinolinic acid in the cerebrospinal fluid of children with symptomatic human immunodeficiency virus type 1 disease: relationships to clinical status and therapeutic response. J Infect Dis. 1993;168:1380-1386.
23. Sci S, Saito K, Stewart SK, et al. Increased HIV-1 DNA content and quinolinic acid concentration in brain tissues obtained from AIDS patients with HIV encephalopathy. / Infect Dis. 1995;172:638-647.
24. Heyes MP, Brew BJ, Martin A, et al. Quinolinic acid in the cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neural. 1991;29:202-209.
25. Deijen JB, van der Beek EJ, Orlebeke JF, van der Berg H. Vitamin B6 supplementation in elderly men: effects on mood, memory, performance and mental effort. Psychopharmacology. 1992;109:489-496.
26. Tang AM, Graham NM, Saah AJ. Effects of micronutrient intake on survival in human immunodeficiency virus type 1 infection. Am J Epidemiol. 1996;143:1244-1256.
27. Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse: a new megavitamin syndrome. N Engl J Hied. 1983;309:445-448.
28. Bernstein AL. Vitamin B6 in clinical neurology. Ann N YAcad Sci. 1990;585:250-260.
29. Bendich A, Cohen M. Vitamin B6 safety issues. Ann N YAcad Sci. 1990;585:321-330.
30. Dommisse J. Subtle vitamin B12 deficiency and psychiatry: a largely unnoticed but devastating relationship? Med Hypotheses. 1991;34:131-140.
31. Ellis FR, Nasser S. A pilot study of vitamin B]2 in the treatment of tiredness. Br J Nutr. 1973;30:277-283.
32. Herbert V, Das KG. Folic acid and vitamin B,r In: Shils ME, Olson JA, Shike M, eds. Modem Nutrition in Health and Disease. Philadelphia, Pa: Lea & Febiger; 1994.
33. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatrie disorders caused by cobalamin deficiency in the absence of pernicious anemia or macrocytosis. A' Engl J Med. 1988;318:1720-1728.
34. Rule SAJ, Hooker SI, Costello C, Luck W, Hoffbrand AY. Serum vitamin B12 and transcobalamin levels in early HIV disease. AmJHematol. 1994;47:167-171.
35. Beach RS, Morgan R, Wilkie F, et al. Plasma vitamin B12 level as a potential cofactor in studies of human immunodeficiency virus type 1-related cognitive changes. Arch Neural. 1992;49:501-506.
36. Herbert V, Fong W, Guile V, Stropler T. Low holotranscobalamin II is the earliest serum marker for subnormal vitamin B12 absorption in patients with AIDS. Am J Hematol. 1990;34:132-139.
37. Healton EB, Savage DG, Brust JC, Garrett TJ, Lindenbaum J. Neurologic aspects of cobalamin deficiency. Medicine. 1991;70:229-245.
38. Saracaceanu E, Tramoni AV, Henry JM. An association between subcortical dementia and pernicious anemia-a psychiatric mask. Compr Psychiatry. 1997;38:349-351.
39. Baldewicz TT, Goodkin K, Blaney NT, et al. Cobalamin level is related to self-reported and clinically rated mood and to syndromal depression in bereaved HIV-1+ and HIV-1homosexual men. J Psychosom Res. 2000;48:177-185.
40. Shor-Posner G, Morgan R, Wilkie F, Eisdorfer C, Baum MK. Plasma cobalamin levels affect information processing speed in a longitudinal study of HIV-1 disease. Arch Neural. 1995;52:195-198.
41. Bell IR, Edman JS, Miller J, et al. Relationship of normal serum vitamin B,2 and folate levels to cognitive test performance in subtypes of geriatric major depression. / Geriatr Psychiatry Neurol. 1990;3:98-105.
42. Bell IR, Edman JS, Morrow FD, et al. B complex vitamin patterns in geriatric and young adult inpatients with major depression. J Am Geriatr Soc. 1991;39:252-257.
43. Perkins DO, Stern RA, Golden RN, Murphy C, Naftolowitz D, Evans DL. Slood disorders in HIV infection: prevalence and risk factors in a nonepicenter of the AIDS epidemic. Am J Psychiatry. 1994;151:233-236.
44. Robertson KR, Stern RA, Hall CD, et al. Vitamin B12 deficiency and nervous system disease in HIV infection. Arch Neurol. 1993;50:807-811.
45. Newbold HL. Vitamin B]2: placebo or neglected therapeutic tool? Med Hypothèses. 1989;28:155-164.
46. Carethers M. Diagnosing vitamin B12 deficiency: a common geriatric disorder. Geriatrics. 1988:43:89-94,105-107,111-112.
47. Hector M, Burton JR. What are the psychiatric manifestations of vitamin B12 deficiency? J Am GeriatrSoc. 1988;36:1105-1112.
48. Levitt AJ, Joffe RT. Vitamin B12 in psychotic depression. Br J Psychiatry. 1988;153:266267.
49. Geagea K, Ananth J. Response of a psychiatric patient to vitamin B therapy. Dis Ken- Sys. 1975;36:343-344.
50. Verbanck PM, Oliver L Changing psychiatric symptoms in a patient with vitamin B,2 deficiency. J Clin Psychiatry. 1991;52:182-183.
51. Evans DL, Edelsolm GA, Golden RN. Organic psychosis without anemia or spinal cord symptoms in patients with vitamin B,2 deficiency. Am J Psychiatry. 1983;140:218-221.
52. Phillips SL, Kahaner KP. An unusual presentation of vitamin B12 deficiency. Am J Psychiatry. 1988;145:529.
53. Zucker DK, Livingston RL, Nakra R, Clayton PJ. B12 deficiency and psychiatric disorders: case report and literature review. Biol Psychiatry. 1981;16:197-205.
54. Tan SV, Guiloff RJ. Hypothesis on the pathogenesis of vacuolar myelopathy, dementia, and peripheral neuropathy in AIDS. / Neural Keurosurg Psychiatry. 1998;65:23-28.
55. DiRocco A, Tagliati M, Danisis F, Dorfman D, Noise J, Simpson DM. A pilot study of Lmethionine for the treatment of AIDS-associated myelopathy. Neurology. 1988;51:266-268.
56. Bottiglieri T. Ademetionine (S-adenosylmethionine) neuropharmacology: implications for drug therapies in psychiatric and neurologic disorders. Opin Imest Drugs. 1997;6:417-426.
57. Dorfman D, DiRicco A, Simpson D, Tagliati M, Tanners L, Moise J. Oral methionine may improve neuropsychological function in patients with AIDS myelopathy: results of an open-label trial. AIDS. 1997;11:1066-1067.
58. Surtees R, Hyland K, Smith I. Central-nervous-system methyl-group metabolism in children with neurological complications of HIV infection. Lancet. 1990;335:619-621.
59. Kieburtz KD, Giang DW, Schiffer RB, Vakil N. Abnormal vitamin B,2 metabolism in human immunodeficiency virus infection. Arch Neural. 1991;48:312-314.
60. Burkes RL, Cohen H, Krailo M, Sinow RM, Cannel R. Low serum cobalamin levels occur frequently in the acquired immune deficiency syndrome and related disorders. EUT J llaematol. 1987;38:141-147.
61. Baum MK, Shor-Posner G, Lu Y, et al. Micronutrients and HIV-1 disease progression. AIDS. 1995;9:1051-1056.
62. Wickramasinghe SN. Morphology, biology, and biochemistry of cobalamin- and folate-deficient bone marrow cells. Baillieres Clin Haematol. 1995:8:441-459.
63. Tang AM, Graham NM, Chandra RK, Saah AJ. Low serum B,2 concentrations are associated with faster human immunodeficiency virus type 1 (HIV-1) disease progression. J Nutr. 1997;127:345-351.
64. Nijst TQ, Wevers RA, Schoonderwaldt HC, Hommes OR, de Haan AFJ. Vitamin BI2 and folate concentrations in serum and cerebrospinal fluid of neurological patients with special reference to multiple sclerosis and dementia. J Neural Neurosurg Psychiatry. 1990;53:951-954.
65. Altay C, Cetin M. Oral treatment in selective vitamin B12 malabsorption. J Pediatr Hematol Oncol 1997;19:245-246.
66. Young SN. The use of dietary components in the study of factors controlling affect in humans: a review. ] Psychiatry Neurosci. 1993;18:235-244.
67. Beach RS, Mantero-Atienza E, Eisdorfer C, Fordyce-Baum MK. Altered folate metabolism in early HIV infection. JAMA. 1988;259:519.
68. Coodley GO, Coodley MK, Nelson HD, Loveless MO. Micronutrient concentrations in the HIV wasting syndrome. AIDS. 1993;7:595-600.
69. Abou-Saleh MT, Coppen A. Serum and red blood cell folate in depression. Ada Psychiatr Scand. 1989;80:78-82.
70. Wesson VA, Levitt AJ, Joffe RT. Change in folate status with antidepressant treatment. Psychiatry Res. 1994;53:313-322.
71. Bell IR, Edman JS, Marby DW, et al. Vitamin BI2 and folate status in acute geropsychiatric inpatients: affective and cognitive characteristics of a vitamin nondeficient population. Biol Psychiatry. 1990;27:125-137.
72. Fava M, Bonis JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T. Folate, vitamin B]2, and homocysteine in major depressive disorder. Am J Psychiatry. 1997;154:426-428.
73. Riedel WJ, Jorissen BL. Nutrients, age and cognitive function. Curr Opin Clin Nutr Metab Care. 1998;l:579-585.
74. Riggs KM, Spiro A III, Tucker K, Rush D. Relations of vitamin BI2, vitamin B6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nulr. 1996;63:306-314.
75. Ebly EM, Schaefer JP, Campbell NR, Hogan DB. Folate status, vascular disease and cognition in elderly Canadians. Age Ageing. 1998;27:485-491.
76. LaRue A, Koehler KM, Wayne SJ, Chiulli SJ, Haaland KY, Carry PJ. Nutritional status and cognitive functioning in a normally aging sample: a 6-y reassessment. Am J Clin Nutr. 1997;65:20-29.
77. Romero-Alvira D, Röche E. The keys ofoxidative stress in acquired immune deficiency syndrome apoptosis. Med Hypotheses. 1998;51:169-173.
78. Favier A, Sappey C, Leclerc P, Faure P, Micoud M. Antioxidant status and lipid peroxidation in patients infected with HIV. Chem Biol Interact. 1994;91:165-180.
79. Baruchel S, Wainberg MA. The role of oxidative stress in disease progression in individuals infected by the human immunodeficiency virus. JLeukoc Biol. 1992;52:111-114.
80. Semba RD, Graham NMH, Caiaffa WT, Margolick JB, Clement L, Vlahov D. Increased mortality associated with vitamin A deficiency during human immunodeficiency virus type 1 infection. Arch Intern Med. 1993;153:21492154.
81. Allard JP, Aghdassi E, Chau J, et al. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects. AIDS. 1998;12:1653-1659.
82. Perrig WJ, Perrig P, Stahelin HB. The relation between antioxidants and memory performance in the old and very old. / Am Gtriatr Soc. 1997;45:718-724.
83. Constans J, Scigneur M, Blann AD, et al. Effect of the antioxidants selenium and betacarotene on HIV-related endothelium dysfunction. Thromb Haemost. 1998;80:1015-1017.
84. Kelly P, Musonda R, Kafwembe E, Kaetano L, Keane E, Farthing M. Micronutrient supplementation in the AIDS diarrhea-wasting syndrome in Zambia: a randomized controlled trial. AIDS. 1999;13:495-500.
85. Pacht ER, Diaz P, Clanton T, Hart J, Gadek JE. Serum vitamin E decreases in HIV-seropositive subjects over time. / Lab Clin Med. 1997;130:293-296.
86. Jordao AA Jr, Silveira S, Figueiredo JF, Vannucchi H. Urinary excretion and plasma vitamin E levels in patients with AIDS. Nutrition. 1998;14:423-426.
87. Joseph JA, Shukitt-Hale B, Denisova NA, et al. Long-term dietary strawberry, spinach, or vitamin E supplementation retards the onset of age-related neuronal signal-transduction and cognitive behavioral deficits. J Neurosci. 1998;18:8047-8055.
88. Keaney JF Jr, Simon DI, Freedman JE. Vitamin E and vascular homeostatis: implications for atherosclerosis. FASEB J. 1999;13:965-975.
89. Carrasquedo F, Glane M, Fraga CG. Tissue damage in acute myocardial infarction: selective protection by vitamin E. free Radie Biol Med. 1999;26:1587-1590.
90. Motoyama T, Kawano H, Kugiyama K, et al. Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spastic angina. JAm Coll Cardiol. 1998:32:1672-1679.
91. Motram P, Shige H, Nestel P. Vitamin E improves arterial compliance in middle-aged men and women. Atherosclerosis. 1999;145:399-404.
92. Chariot P, Perchet H, Monnet I. Dilated cardiomyopathy in HIV-infected patients. A' Engl JMed. 1999;340:732.
93. Tang AM, Graham NM, Semba RD, Saah AJ. Association between serum vitamin A and E levels and HIV-1 disease progression. AIDS. 1997:11:613-620.
94. Gogu SR, Beckman BS, Rangan SR, Agrawal KC. Increased therapeutic efficacy of zidovudine in combination with vitamin E. Biochem Biophys Res Commun. 1989;165:401-407.
95. Adler LA, Peselow E, Rotrosen J, et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry. 1993;150:1405-1407.
96. Egan MF, Hyde TM, Albers GW, et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992;149:773-777.
97. Constans J, Conri C, Sergeant C. Selenium and HIV infection. Nutrition. 1999;15:719-720.
98. Chariot P, Dubreuil-Lemaire M-L, Zhou JY, et al. Muscle involvement in human immunodeficiency virus-infected patients is associated with marked selenium deficiency. Muscle Nene. 1997;20:386-389,
99. Kiremidjian-Schumacher L, Stotzky G. Selenium and immune responses. Environ Res. 1987;42:277-303.
100. Look MP, Rockstroh JK, Rao GS, Kreuzer KA, Spengler U, Sauerbruch T. Serum selenium vs lymphocyte subsets and markers of disease progression and inflammatory response in human immunodeficiency virus-1 infection. Biol Trace Elem Res. 1997;56:31-41.
101. Baum MK, Shor-Posner G, Lai S, et al. High risk of HIV-related mortality is associated with selenium deficiency. J Acquir Immune Defic Syndrllum Retrovirol. 1997;15:370-374.
102. Campa A, Shor-Posner G, Indacochea F, et al. Mortality risk in selenium-deficient HIV-positivie children. J Acquir Immune Deflc Syndr Hum Retroiirol. 1999;20:508-513.
103. Koch J, N'eal EA, Schlott MJ, et al. Zinc levels and infections in hospitalized patients with AIDS. Nutrition. 1996;12:515-518.
104. Macs M, DTIaese PC, Schärpe S, D'Hondt P, Cosyns P, De Broe ME. Hypozincemia in depression. J Affect Disord. 1994;31:135-140.
105. Macs M, Vandoolaeghe E, fN'eels H, et al. Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol Psychiatry. 1997;42:349-358.
106. Baldewicz T, Goodkin K, Feaster DJ, Blaney N'T, Shor-Posner G, Baum M. Zinc deficiency is related to depressed mood in recently bereaved HIV-1+ and HIV-1- homosexual men. Psychosom Med. 1998;60:101.
107. Ripa S, Ripa R. Zinc and immune function. Minen-a Med. 1995;86:315-318.
108. Mossad SB, Macknin ML, Medendorp SV, Mason P. Zinc gluconate lozenges for treating the common cold, a randomized, doubleblind, placebo-controlled study. Ann Intern Med. 1996;125:81-88.
109. Graham N'M, Sorenson D, Odaka N, et al. Relationship of serum copper and zinc levels to HIV-1 seropositivity and progression to AIDS. J Acquir Immune Defic Syndr Hum Retroiirol. 1991;4:976-980.
110. Fabris N, Mocehegiani E, Galli M, Irato L, Lazzarin A, Moroni M. AIDS, zinc deficiency, and thymic hormone failure. JAMA. 1988;259:839-840.
111. Mocehegiani E, Muzzioli M, Gaetti R, Veccia S, Vilicehi C, Scalise G. Contribution of zinc to reduce CD 1+ risk factor for "severe" infection relapse in aging: parellelism with HIV. Int J Immunopharmacol. 1999;21:271-281.
112. Fahris N. Neuroendocrine-immune aging: an integrative view on the role of zinc. Ann A' 1' AcadSci. 1994;719:353-368.
113. Begin ME, Manku MS, Horrobin DF. Plasma fatty acid levels in patients with acquired immune deficiency syndrome and in controls. Prostaglandins Leukot Essent Fatly Acids. 1989;37:135-137.
114. Kinchington D, Randall S, Winther M, Horrobin D. Lithium gammalinolenate-induced cytotoxicity against cells chronically infected with HIV-1. FEES Lett. 1993;330:219-221.
115. Yehuda S, Rabinovitz S, Mostofsky DI. Essential fatty acids are mediators of brain biochemistry and cognitive functions. J Neurosci Res. 1999;56:565-570.
116. Kaplan RJ, Greenwood CE. Dietary saturated fatty acids and brain function. Neurochem Res. 1998;23:615-626.
117. Stol1 AL, Severus WE, Freeman MP, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999;56:407-412.
118. Crook MA, Mir N'. Abnormal lipids and the acquired immunodeficiency syndrome: is there a problem and what should we do about it? Int J STD AIDS. 1999;10:353-356.
119. Shor-Posner G, Basil A, Lu Y, et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med. 1993;91:515-519.
120. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglycéride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045-1052.
121. Zangerle R, Sarclelti M, Gallati H, Reibnegger G, Wächter H, Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr Hum Retrorirol. 1994;7:1149-1156.
122. Shor-Posner G, Baldewicz T, Feaster D, et al. Psychological distress in HIV-1 disease in relationship to hypocholesterolemia. Int J Psychiatry Med. 1997;27:159-171.
123. Heron DS, Shinitsky M, Hershkowitz M, Samuel D. Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes. Proc Nail Acad Sci U S A. 1980;77:7613-7617.
124. Dong KL, Bausserman LL, Flynn MM, et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active anliretroviral therapy (HAART). J Acquir Immune Deβc Syndr Hum Retrorirol. 1999;21:107-113.
125. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors: the Swiss HIV Cohort study. Circulation, 1999;100:700-705.
126. Echevarria KL, Hardin TC, Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother. 1999;33:859-863.
127. Martinez E, Gonget I, Lozano L, Casamitjana R, Galell J.M. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13:805810.
128. Baum MK, Shor-Posner G, Zhang G, et al. HIV-1 infection in women is associated with severe nutritional deficiencies. J Acquir Immune Defic Syndr Hum Retrorirol. 1997;16:272-278.
129. Semba RD, Farzadegan H, Vlaliov D. Vitamin A levels and human immunodeficiency virus load in injection drug users. Clin Diagn Lab Immunol. 1997;4:93-95.
130. Winick M. Malnutrition and Brain Development. New York, N'Y: Oxford University Press; 1976.
131. Cordero ME, Trejo M, Garcia E, Barros T, Colombo M. Dendritic development in the neocortex of adult rats subjected to postnatal malnutrition. Early Hum Dei: 1985;12:309321.
132. Galler G, Ramsey F. Influence of early malnutrition on subsequent behavioral development: child's behavior at home. / /1m Acad Child Psychiatry. 1985;24:58-64.
133. Stoch MB, Smythe PM. 15-year developmental study on effects of severe undernutrition during infancy on subsequent physical growth and intellectual functioning. Arch Dis Child. 1976;51:327-336.
134. Cunningham-Rundles S, Kirn SH, Dnistrian A, et al. Micronutrient and cytokine interaction in congential pédiatrie HIV infection. J Xutr. 1996;126:S2674-S2679.
135. Periquet BA, Jammes NM, Lambert WE, et al. Micronutrient levels in HIV-1-infected children. AIDS. 1995;9:887-893.
136. Bromvers P, DeCarli C, Heyes MP, et al. Neurobehavioral manifestations of symptomatic HIV-1 disease in children: can nutritional factors play a role? J Nutr. 1996;126:S2651-S2662.
137. Agostoni C, Zuccotti GV, Riva E, et al. Low levels of linoleic acid in plasma total lipids of HIV-1 seropositive children. J Am Coll A'ufr. 1998;17:25-29.
138. Brouwers P, DeCarli C, Tudor-Williams G, Civitello L, Moss H, Pizzo P. Interrelations among patterns of change in neurocognitive, CT brain imaging, and CD4 measures associated with antiretroviral therapy in children with symptomatic HIV infection. . Adi tieuroimmunol. 1994;4:223-231.
139. Dolan RJ, Mitcbell J, Wakeling A. Structural brain changes in patients with anorexia nervosa. PsychollMed. 1988;18:349-353.
140. Grantham-McGregorSM, Powell CA, Walker SP, Hirnes JH. Nutritional supplementation, psychosocial stimulation, and mental development of stunted children: the Jamaican Study. Lancet. 1991;338:l-5.
141. Brouwers P, Moss H, Wolters P, et al. Effect of continuous-infusion zidovudine therapy on neuro-psychologic functioning in children with symptomatic human immuno-deficiency virus infection. J Peiliatr. 1990;117:980-985.